Massachusetts Financial Services CO Vertex Pharmaceuticals Inc Transaction History

Massachusetts Financial Services CO

$321 Billion
Q1 2024

A detailed history of Massachusetts Financial Services CO transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Massachusetts Financial Services CO holds 2,804,188 shares of VRTX stock, worth $1.28 Billion. This represents 0.37% of its overall portfolio holdings.

Number of Shares

2,804,188

Previous 3,625,802 22.66%

Holding current value

$1.28 Billion

Previous $1.48 Billion 20.55%

% of portfolio

0.37%

Previous 0.49%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$407.69 - $446.08 $335 Million - $367 Million	-821,614 Reduced 22.66%	2,804,188 $1.17 Billion
Q4 2023 Feb 08, 2024	SELL	$343.0 - $410.68 $91.2 Million - $109 Million	-265,992 Reduced 6.83%	3,625,802 $1.48 Billion
Q3 2023 Nov 08, 2023	SELL	$338.18 - $362.46 $16.7 Million - $17.9 Million	-49,327 Reduced 1.25%	3,891,794 $1.35 Billion
Q2 2023 Aug 09, 2023	SELL	$314.42 - $351.91 $32.7 Million - $36.6 Million	-103,910 Reduced 2.57%	3,941,121 $1.39 Billion
Q1 2023 May 10, 2023	SELL	$283.23 - $323.1 $18.8 Million - $21.5 Million	-66,524 Reduced 1.62%	4,045,031 $1.27 Billion

Q4 2022 Feb 13, 2023	SELL	$285.76 - $321.48 $67.2 Million - $75.6 Million	-235,176 Reduced 5.41%	4,111,555 $1.19 Billion
Q3 2022 Nov 09, 2022	BUY	$273.83 - $305.53 $1.26 Million - $1.41 Million	4,619 Added 0.11%	4,346,731 $1.26 Billion
Q2 2022 Aug 09, 2022	BUY	$234.96 - $292.55 $194 Million - $242 Million	826,959 Added 23.53%	4,342,112 $1.22 Billion
Q1 2022 May 11, 2022	BUY	$221.42 - $260.97 $71 Million - $83.6 Million	320,475 Added 10.03%	3,515,153 $917 Million
Q4 2021 Feb 10, 2022	BUY	$177.01 - $223.45 $8.04 Million - $10.2 Million	45,438 Added 1.44%	3,194,678 $702 Million
Q3 2021 Nov 10, 2021	SELL	$181.39 - $202.99 $824,780 - $922,995	-4,547 Reduced 0.14%	3,149,240 $571 Million
Q2 2021 Aug 13, 2021	BUY	$187.49 - $221.1 $55.7 Million - $65.7 Million	297,171 Added 10.4%	3,153,787 $636 Million
Q1 2021 May 13, 2021	BUY	$207.02 - $241.31 $46.1 Million - $53.7 Million	222,507 Added 8.45%	2,856,616 $614 Million
Q4 2020 Feb 12, 2021	BUY	$207.01 - $276.09 $152 Million - $203 Million	733,952 Added 38.63%	2,634,109 $623 Million
Q3 2020 Nov 12, 2020	BUY	$255.65 - $303.1 $23.5 Million - $27.8 Million	91,876 Added 5.08%	1,900,157 $517 Million
Q2 2020 Aug 11, 2020	BUY	$225.48 - $295.8 $131 Million - $172 Million	581,495 Added 47.4%	1,808,281 $525 Million
Q1 2020 May 14, 2020	BUY	$199.77 - $247.81 $20.6 Million - $25.6 Million	103,158 Added 9.18%	1,226,786 $292 Million
Q4 2019 Feb 13, 2020	SELL	$166.71 - $223.91 $16.1 Million - $21.6 Million	-96,312 Reduced 7.89%	1,123,628 $246 Million
Q3 2019 Nov 05, 2019	SELL	$166.23 - $187.09 $120 Million - $135 Million	-720,436 Reduced 37.13%	1,219,940 $207 Million
Q2 2019 Aug 14, 2019	SELL	$164.61 - $190.37 $5.8 Million - $6.7 Million	-35,218 Reduced 1.78%	1,940,376 $356 Million
Q1 2019 May 13, 2019	BUY	$163.73 - $194.7 $10.6 Million - $12.6 Million	64,583 Added 3.38%	1,975,594 $363 Million
Q4 2018 Feb 08, 2019	BUY	$151.91 - $192.21 $10.8 Million - $13.7 Million	71,366 Added 3.88%	1,911,011 $317 Million
Q3 2018 Oct 25, 2018	BUY	$167.73 - $192.74 $29.5 Million - $33.9 Million	176,093 Added 10.59%	1,839,645 $355 Million
Q2 2018 Jul 30, 2018	BUY	$145.72 - $169.96 $20.9 Million - $24.4 Million	143,730 Added 9.46%	1,663,552 $283 Million
Q1 2018 May 04, 2018	BUY	$151.6 - $177.13 $230 Million - $269 Million	1,519,822 New	1,519,822 $248 Million

Others Institutions Holding VRTX

# of Institutions

1,623

Shares Held

222M

Call Options Held

1.35M

Put Options Held

1.49M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $117B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Massachusetts Financial Services CO , based on Form 13F filings with the SEC.

News

Stay updated on Massachusetts Financial Services CO with notifications on news.

Account

Massachusetts Financial Services CO Vertex Pharmaceuticals Inc Transaction History